

## The State of the Cytokine Status in Pregnant Women with Fetal Growth Retardation

Mavlyanova N.N.<sup>1</sup>, Ixtiyarova G.I.<sup>2</sup>, Tosheva I.I.<sup>2</sup>, Aslonova M.Zh<sup>2</sup> and Narzullaeva N.S<sup>2</sup>

<sup>1</sup>Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology under the Ministry of Health of the Republic of Uzbekistan.

<sup>2</sup>Department of Obstetrics and Gynecology, Bukhara State Medical Institute. Abu Ali Ibn Sina of the Ministry of Health of Uzbekistan.

### \*Correspondence:

Mavlyanova N.N, Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology under the Ministry of Health of the Republic of Uzbekistan.

**Received:** 11 may 2020; **Accepted:** 01 June 2020

**Citation:** Mavlyanova N.N, Ixtiyarova G.I, Tosheva I.I, et al. The State of the Cytokine Status in Pregnant Women with Fetal Growth Retardation. J Med - Clin Res & Rev. 2020; 4(6): 1-4.

### ABSTRACT

*The article provides a study of cytokine status in fetal growth retardation. The study reveals that pregnant women with severe fetal growth retardation have an increased concentration of pro- (IL-6, FNO-alfa, INF-g) and anti-inflammatory cytokines (IL-4 and IL-6), along with an increase in cytotoxic reactions in the placenta, development of systemic endothelial dysfunction with an autoimmune process, which cause angiogenesis disorders.*

### Keywords

Fetal growth restriction syndrome, Fetoplacental insufficiency, cytokines (FNO-alfa, INF-gamma, IL-4 and IL-6, IL-10).

### Introduction

According to numerous studies, in most cases, the favorable course of pregnancy depends on the immunological control of the relationship between the mother and the fetus. One of the most important tasks of modern obstetrics is to reduce reproductive losses which refer to fetal loss throughout the gestation period, as well as the death of children in early neonatal age [1,3,4,5,8,10,14,15,22]. It should be mentioned that placental insufficiency (PI) accounts to more than 35% of causes of perinatal and infant mortality [6,7,8,16,18,20].

The main clinical manifestations of PI are chronic intrauterine hypoxia and fetal growth retardation (FGR) - intrauterine growth retardation. It is intrauterine hypoxia and FGR that can cause abortion and fetal death, as well as the occurrence of somatic, mental and reproductive pathologies in further periods of individual development [19].

So far, the mechanisms for the immunological control of trophoblast invasion into the uterine wall have already been studied, as well as the mechanisms for the formation of immunological tolerance in the mother - fetus system. However, there is still no consensus on the nature of changes in the placental cytokine network in the

physiological pregnancy and obstetric pathology, especially in fetal growth retardation [10].

An integrated approach to the study of immunological regulatory mechanisms, the role of cellular factors in controlling both normal and pathological placenta development shall contribute to the disclosure of immunopathogenesis in fetal growth retardation.

The study aimed to assess the status of pro- and anti-inflammatory cytokines in the clinical course of fetal growth retardation.

### Materials and Methods

We examined 103 pregnant women aged 19 to 45 years. All the women have been kept under observation at the clinic of the State institution, Republican specialized scientific and practical medical center obstetrics and gynecology under the Ministry of Health of the Republic of Uzbekistan. All pregnant women underwent general clinical, functional, and immunological ELISA studies. All pregnant women consulted with other specialists - a neurologist, therapist, cardiologist, hematologist, a specialist in communicable diseases, etc.

Serum cytokines levels were measured via enzyme-linked immunosorbent assay (ELISA). To measure the levels of cytokines FNO-alfa, INF-gamma, IL-4 and IL-6, IL-10, we used the test systems developed at ZAO Vector-Best (Novosibirsk).

These test systems are based on the sandwich method of solid-phase ELISA using horseradish peroxidase as an indicator enzyme. After the completion of the main stages of work, 10–15 minutes before the end of the incubation, a solution of the substrate – chromogenic mixture was prepared. Then, the cells of the plate were washed three times by adding 300 µl of washing physiological saline into each of them and 3-5 times with distilled water, followed by its removal by shaking the plate over the sink. Finally, 200 µl of a substrate-chromogenic mixture solution was added to all wells, which was followed by 20-minutes incubation at room temperature in the dark place. The reaction was stopped by adding 50 µl of a solution of sulfuric acid. The results, which express the activity of bound peroxidase, were analyzed via an automatic microtroy photometer at a wavelength of 492 nm, with zero absorbance in standertized wells set without detectable cytokine in solution. To perform the quantitative assessment of the results, the calibration curve was drawn manually; the curve reflects the dependence of optical density on standard antigen concentration, and the studied samples can be compared with the curve.


## Results

Clinical and laboratory studies of 66 pregnant women with fetal growth retardation contributed to the determination of severity. So, for example, 39 pregnant women received the diagnosis of FGR-I severity, which amounted to 59.1%, while 24 women (36.6%) had FGR-II severity and 3 pregnant women were diagnosed with FGR-III severity, which amounts to 4.5% of cases.

The study of concomitant pathology in 103 examined pregnant women revealed concomitant somatic disease in 48 of them, which amounts to 46.6%.

The most frequent concomitant diagnoses were: blood disorders (anemia) – 40,7% (42), urogenital disorders – 39,8% (41), cardiovascular disorders – 22,3% (23); 5,8% had hepatitis (6) and 4,8% (5) had endocrine systems disorders.

Whereas, in the group of pregnant women with FGR, the most frequently diagnosed diseases were: urogenital disorders - 51.2% (34 out of 66), anemia - 45.5% (30), cardiovascular disease - 34.8% (23), endocrinopathy - 7, 6% (5) and hepatitis - 9.1% (6) cases, respectively. In the group of pregnant women without FGR, 12 out of 37 were diagnosed with anemia (32.4%) and 18.9% (7) women had urogenital disorders.



**Figure 1:** Concomitant disorders in pregnant women (with account for FGR), % When analyzing the results of immunological studies, due to a very low amount of the detected cases of FGR-III severity, these pregnant women were included in the group of FGR-II severity (Table 1).

**Table 1:** Cytokine status indicators in pregnant women with fetal growth retardation (pg/ml).

Group	FNO-alfa	IL4	INF-g	IL-10	IL-6
control group N = 35	5,8 ± 0,9	4,2 ± 0,8	5,5 ± 0,9	10,2 ± 0,9	7,6 ± 0,8
pregnant women without FGR N = 37	15,8 ± 0,3*	5,1 ± 0,04	6,4 ± 0,07	11,03 ± 0,2	17,9 ± 0,5*
pregnant women with FGR N = 66	21,4 ± 0,2**	7,7 ± 0,1**	7,8 ± 0,07**	13,2 ± 0,09**	24,8 ± 0,2**

Note: \* - the measure of reliability in relation to the control group (P <0.05).

\*\* - the measure of reliability in relation to indicators of pregnant women without FGR (P <0,05).

As follows from table, the level of the pro-inflammatory cytokine INF-g averaged 6.4 ± 0.07 pg/ml, which is 1.2 times higher than the control group, but it was not reliable (P > 0.05). The levels of anti-inflammatory cytokines IL-4 and IL-6 also slightly exceeded those of the control individuals, however, they also were unreliable and averaged 5.1 ± 0.04 and 11.03 ± 0.2 pg/ml, respectively (4,2 ± 0,8 and 10,2 ± 0,9 pg/ml in control, P >0,05).

At the same time, the level of proinflammatory cytokines FNO-alfa and IL-6 in the group of pregnant women without FGR averaged 15.8 ± 0.3 pg/ml and pg/ml 17.9 ± 0.5, which is 2.7 and 2, 4 times higher than the control group, respectively (P <0.05). This phenomenon is possibly associated with concomitant pathology of pregnant women without FGR - with the urogenital and blood system (anemia) disorders, which reflects the response of the cellular immune system to bacterial infections in the body.


According to published data, cytokines, germ factors, and chemokines are secreted by various placenta cells throughout pregnancy; they determine the different aspects of the interaction of placenta cells with each other and determine the processes of trophoblast invasion and formation of the vasculature, and inhibit the maternal cytotoxic immune report against fetus [23].

Notably, an increase in the concentration of proinflammatory cytokines FNO-alfa and IL-6 in pregnant women with a physiological course of pregnancy can also be explained by an increase in their anti-apoptotic role in relation to placenta cells and stabilization of proliferative processes in placental tissue, which cause a compensatory reaction in response to an increase in antiangiogenic stimuli in the placental stroma [10].

The study of the state of pro- and anti-inflammatory cytokines in the group of pregnant women with FGR showed a significant increase in their levels compared to the group of pregnant women

with a physiological course of pregnancy. Thus, the concentrations of pro-inflammatory cytokines FNO-alfa, INF-g, and IL-6 were 1.4, 1.2, and 1.4 times higher than in pregnant women without FGR and averaged to  $21,4 \pm 0,2$  pg/ml,  $7,8 \pm 0,07$ pg/ml и  $24,8 \pm 0,2$ pg/ml, respectively. The results were statistically significant ( $P < 0.05$ ;  $P < 0.001$ ). The level of anti-inflammatory cytokines IL-4 and IL-10 in this group of pregnant women is statistically significantly increased ( $P < 0.05$ ). According to the data published, the data obtained reflect the activation of placental macrophages [25]. An increase in the concentration of IL-6, FNO-alfa, INF-g and anti-inflammatory cytokines IL-4 and IL-10 reflects an imbalance in the cytokine system due to increased activity of placental macrophages and activation of placental endothelial cells.

The data obtained were also analyzed with account of the severity of FGR in pregnant groups (Figure 2).



**Figure 2:** Indicators of cytokine status in pregnant women, with account of the FGR severity (pg/ml) ( $P < 0,05$ ).

As can be seen from Figure 2, the level of FNO-alfa and IL-6 in the group of pregnant women with FGR-I severity was 1.3 and 1.4 times higher than in the group of pregnant women with normal course of pregnancy, this difference is statistically significant ( $P < 0.05$ ). Whereas, in pregnant women with FGR-II severity, the level of FNO-alfa and INF-g was 1.1 and 1.2 times higher than in pregnant women with FGR-I severity and averaged  $22.2 \pm 0.1$  pg/ml and  $8.3 \pm 0.08$  pg/ml, respectively. ( $P < 0.05$ ).

We have estimated the Spearman rank correlation coefficient for cytokine concentrations. This, in the group of pregnant women with FGR-I severity, the level of FNO-alfa had a direct significant positive correlation with the IL-4 indicator -  $r = + 0.5$  ( $P < 0.05$ ), and IL-6 had an inverse correlation with the anti-inflammatory cytokine IL -4 -  $r = -0.3$  ( $P < 0.05$ ). Such a significance of the cytokine status in pregnant women with FGR-I severity causes acute inflammatory process, which may be due to urogenital disorders, etc.

In women with FGR-II severity, an increased level of INF-g had a direct correlation with FNO-alfa -  $r = + 0.4$  and IL-10 -  $r = + 0.3$  ( $P < 0.05$ ), maintaining active inflammatory process. The anti-inflammatory cytokine IL4 had a significant inverse correlation with IL-10 and IL-6 ( $r = -0.4$ ,  $P < 0.05$ ), respectively.

Comparison of the obtained results with the published sources reveals that increased levels of pro- (IL-6, FNO-alfa, INF-g) and anti-inflammatory cytokines (IL4 and IL-6) in the body of pregnant women with FGR-II severity characterizes an increase in cytotoxic reactions in the placenta, development of systemic endothelial dysfunction with an autoimmune process, causing disorders in angiogenesis and possibly the formation of mononuclear infiltrates in the placental tissue.

Thus, fetal growth retardation is associated with disorders in interaction between the placental tissue and the mother's immune system, which leads to disorders in the cytokine status in the pregnant body (mother-placenta-fetus) due to an increase in the concentration of pro- (IL-6, FNO-alfa, INF-g) and anti-inflammatory (IL-4, IL-10) cytokines, which is accompanied by the placenta damage, increased death of trophoblast cells and endothelial cells of the placental vessels.

## References

1. Abdusamadova MF, Karimov AKh. The influence of some risk factors during pregnancy on the development of the fetal growth retardation. Materials of the Republican Conference Obstetric Bleeding New Technologies for Prevention and Treatment. News of Dermatovenereology and Reproductive Health. Tashkent. 2016; 73: 172.
2. Avrutskaya VV, Orlov VI, Ponamareva AYU, et al. Changes in the endothelial system of the vessels of pregnant women in gestosis. Russian Bulletin of the Obstetrics-Gynecologist. 2007; 1: 1-7.
3. Ailamazyan EK, Kulakov VI, Radzinsky VE, et al. National Guideline. Obstetrics. 2007; 637.
4. Afanasyeva NV. Obstetric tactics in various severities of fetoplacental insufficiency. thesis for a Candidate Degree in Medical Sciences. 2004.
5. Ahmed-zade VA. Pregnancy and delivery in antiphospholipid syndrome course perinatal outcomes Medical News. 2011; 5: 81-85.
6. Bikmetova ES, Trishkin AG. Proliferation of umbilical cord vein endothelial cells and hormonal and metabolic features of the fetoplacental complex in delivery in fetal growth retardation scientific publication. Questions of gynecology obstetrics and perinatology. 2014; 13: 31-35.
7. Zaydieva ZS, Tyutyunnik VL, Danchenko OV, et al. Clinical and morphological parallels of the fetoplacental complex in herpetic infection in pregnant women. Bulletin of the Russian Association of Obstetricians-Gynecologists. 2009; 2: 34-36.
8. Ignatko IV. Pregnancy with high risk of perinatal pathology pathogenesis of placental insufficiency early diagnosis and obstetric tactics. Doctoral dissertation. 2005.
9. Makarova OV, Aleshkina VV, Savchenko TA. Infections in obstetrics and gynecology. Medpressinform. 2007; 464.
10. Sokolov DI, Selkov SA, Aylamazyan EK. Immunological control of the formation of placental vasculature. Publishing house. 2012; 208.
11. Karimov AK, Karamanyan AA, Nigmatullina II. The state of hemostasis in normal pregnancy and in pregnancy

- complicated by preeclampsia. Constitution of the Republic of Uzbekistan youth education and upbringing. Materials of the second traditional scientific-practical conference. Tashkent. 2013; 96-101.
12. Kakhramonova VA, Torchinov AM, Mayev IV. Liver functional change in women who have undergone gestosis a clinical and laboratory rationale for choosing a correction method. The issues of gynecology obstetrics and perinatology. 2007; 6: 43-47.
  13. Kokolina VF, Kartelishvili AV, Vasilyeva OA. Fetal-placental insufficiency pathogenesis, diagnosis, therapy, prevention a guide for doctors. M Me-practice M. 2006.
  14. Krivoruchko AY, Aksenenko VA, Kvochko AN, et al. Production of cytokines by the culture of chorionic villi in hypoxia in patients with late gestosis. Journal of obstetrics and gynecological diseases. 2000; 10: 82-85.
  15. Krukier II, Pogorelova TN. Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord in normal and complicated pregnancy. Bull. for exp. biol. and medicine. 2006; 2: 177-179.
  16. Kuzmin VN, Adamyan LV, Muzykantova VS. Placental insufficiency in viral infections M. 2005; 103.
  17. Makatsaria AD, Bitsadze VO, Akinyshina SV. Systemic inflammatory response in obstetrics. M MIA. 2006; 54-74.
  18. Rybin MV. Placental insufficiency in gestosis pathogenesis diagnosis assessment of severity and obstetric tactics Doctoral dissertation. 2007.
  19. Strizhakov AN, Ignatko IV, Timokhina EV, et al. Fetal growth retardation pathogenesis diagnosis treatment obstetric tactics. M GEOTAR Media. 2014; 120.
  20. Tetrushvili NK. The role of immune interactions in the early stages of physiological pregnancy and in recurrent miscarriage. Immunology. 2008; 29: 124-129.
  21. Filchenkov AA. Caspase regulators of apoptosis and other cellular functions. Biochemistry. 4: 453-466.
  22. Yarin AA, Nikonova MF, Yarin AA, et al. Apoptosis the role in pathology and significance of its assessment in clinical and immunological examination of patients. Medical immunology. 2000; 2: 7-16.
  23. Goldman-Wohl DS, Ariel I, Greenfield C, et al. Tie-2 and angiopoietin-2 expression at the fetal-maternal interface a receptor ligand model for vascular remodeling. Mol. Hum. Reprod. 2000; 6: 88-95.
  24. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008; 21: 279-287.
  25. Yie SM, Li LH, Li YM, et al. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am J Obstet Gynecol. 2004; 58: 185-190.
  26. Weber C, Schober A, Zernecke A. Chemokines key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb vasc Biol. 2004; 24: 1997-2008.
  27. Wei J, Satomi M, Negishi Y, et al. Effect of sera on the adhesion of natural killer cells to the endothelium in severe preeclampsia. J Obstet Gynaecol Rec. 2006; 32: 443-448.
  28. Ikhtiyarova GI, Aslonova MZh. Microbiological and hormonal characteristics of the formation of an undeveloped pregnancy. Fundamental and practical issues of immunology and infectious pathology Collection of scientific articles of the participants Int. scientific and practical conference. 2018; 9-15.
  29. Ikhtiyarova GA, Kilicheva V, Rozikova D, et al. Microbiological changes in pregnancy with antenatal death of fetus. Journal of research in health science. Crossref. 2018; 1: 18-22.